Who is sponsoring NCT05087498?

NCT05087498 is sponsored by Guangdong Women and Children Hospital.

What drugs are being tested in NCT05087498?

Interventions in NCT05087498: autologous cord blood mononuclear cells, normal saline.

What condition does NCT05087498 study?

NCT05087498 studies Immunomodulation Effect.

Is NCT05087498 still recruiting?

NCT05087498 is currently completed. Last updated 2 January 2024.

Last reviewed 2024-01-02 · How we verify

NCT05087498

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Autologous Cord Blood-mononuclear Cells Infusion on Immune Microenvironment in Infants Born Very Preterm in NICU

Completed Phase 1 Last updated 2 January 2024

What this trial tests

Phase 1 trial testing autologous cord blood mononuclear cells in Immunomodulation Effect in 8 participants. Completed in 18 August 2022.

Timeline

28 November 2021

Primary endpoint
18 August 2022

18 August 2022

Quick facts

Lead sponsor	Guangdong Women and Children Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	8
Start date	28 November 2021
Primary completion	18 August 2022
Estimated completion	18 August 2022
Sites	1 location across China

Drugs / interventions tested

autologous cord blood mononuclear cells — full drug profile →
normal saline

Conditions studied

Immunomodulation Effect — all drugs for Immunomodulation Effect →

Sponsor

Guangdong Women and Children Hospital

Who can join

Adults 24 Weeks to 32 Weeks, any sex, with Immunomodulation Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multi-omics (analysis of peripheral blood immune cells subset, peripheral blood MNCs transcriptome, soluble inflammatory cytokine profile in blood and airway secretion, lung and gut microbiota, and the interaction) analysis was used to profile immune alternation of infants with intravenous ACBMNC infusion in very preterm monozygotic twins

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Autologous cord blood mononuclear cell infusion for the prevention of bronchopulmonary dysplasia in very preterm monozygotic twins: A study protocol for a randomized, placebo-controlled, double-blinded multicenter trial.
Zhuxiao R, Ruoyu H, Liling Y, Xuejun R, et al · · 2022 · PMID 36568414 · DOI 10.3389/fped.2022.884366

Verify or expand the search:

Other trials of autologous cord blood mononuclear cells

Trials testing the same drug.

NCT05071638 — Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neona · Phase 3 · unknown
NCT04440670 — Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Pre · Phase 3 · unknown

Other Guangdong Women and Children Hospital trials

Trials by the same sponsor.

NCT07519213 — Postoperative Hormonal Therapy and Recurrence After Surgery for Ovarian Endometrioma · completed
NCT06206590 — Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates · unknown
NCT06371313 — Endocrine, Metabolic and Inflammatory Characteristics of Offspring of Mothers With PCOS Hyperandrogenism · completed
NCT05872425 — Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS · NA · completed
NCT05976529 — A Multicenter, Observational Clinical Study of Dydrogesterone · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05087498 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Women and Children Hospital
Last refreshed: 2 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05087498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing